 It has orphan drug status in the United States for acanthamoeba keratitis and primary amebic meningoencephalitis (PAM).Miltefosine is listed as pregnancy category D by the FDA.This means there is evidence-based adverse reaction data from investigational or marketing experience or studies in humans of harm to the human fetus.